Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

By

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

By

Investigators identify a novel role of the genes located on chr17p13 in the induction of apoptosis in multiple myeloma.

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

By

Continuous therapy appears to be the preferred treatment modality in newly diagnosed patients with multiple myeloma (MM).

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

By

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T

By

BCMA expression did not correlate with clinical response.

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout

By

A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.

CAR-T Cells Successfully Manufactured at Point-of-Care

CAR-T Cells Successfully Manufactured at Point-of-Care

By

CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma

By

Patients saw a deepening of responses over time.

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted

By

AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

By

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models

By

The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM

By

Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

By

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

Phase 3 POLLUX Study: Three-Year Follow-Up

Phase 3 POLLUX Study: Three-Year Follow-Up

Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes

By

Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo

Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma

Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma

Sundar Jagannath, MD, discusses his findings at ASH 2018.

ASH 2018: New Developments in Treatment of Multiple Myeloma

ASH 2018: New Developments in Treatment of Multiple Myeloma

Robert Rifkin, MD, FACP, discusses the latest research being presented at ASH 2018.

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value

By

Stringent CR criteria may not predict clinical outcomes for patients with MM.

The Role of Salvage Autologous Transplant in the Treatment of Multiple Myeloma

The Role of Salvage Autologous Transplant in the Treatment of Multiple Myeloma

By

Results of a comparison study, presented at ASH 2018, found that salvage HDCT followed by ASCT in patients with relapsed MM did not lead to significant difference in PFS or OS compared with continuous novel agent-based treatment.

Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes

Predicting Outcomes After Hematopoietic Stem Cell Transplant for Myelodysplastic Syndromes

By

A personalized prediction model for probability of survival in patients with MDS who undergo HCT is presented at the ASH 2018 Annual Meeting.

Phase 1, 2 Study Data on Venetoclax for MM

Phase 1, 2 Study Data on Venetoclax for MM

Rod A. Humerickhouse, MD, PhD, discusses phase 1, 2 findings on venetoclax for multiple myeloma.

 NKG2D CAR T Cells: No Robust Efficacy Signal in Phase 1

NKG2D CAR T Cells: No Robust Efficacy Signal in Phase 1

By

Phase 1 results support further development.

Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

By

Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Daratumumab Plus Lenalidomide and Dexamethasone May Benefit Some Patients With MM

Daratumumab Plus Lenalidomide and Dexamethasone May Benefit Some Patients With MM

By

Patients were randomly assigned to receive either daratumumab in combination with lenalidomide (an immunomodulatory drug) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

By

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

Transplant May Be a Valid Treatment Option for Older Patients with Myeloma

Transplant May Be a Valid Treatment Option for Older Patients with Myeloma

By

In select older patients, transplant improved survival outcomes compared with patients who did not receive autologous stem cell transplantation.

CD56-Targeting ADC Found Safe and Active in Relapsed or Refractory Multiple Myeloma

CD56-Targeting ADC Found Safe and Active in Relapsed or Refractory Multiple Myeloma

By

Although nearly half of patients had stable disease after study treatment, none of the patients achieved a very good partial response or a complete response.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs